Rolph Timothy 4

4 · Akero Therapeutics, Inc. · Filed Nov 28, 2025

Form 4

Period: 2025-11-25

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock
2025-11-25$28.35/sh+3,527$99,990→ 132,998 total
Exercise/Conversion
Common Stock
2025-11-25$6.36/sh+43,064$274,059→ 176,062 total
Exercise/Conversion
Common Stock
2025-11-25$21.09/sh+4,284$90,350→ 180,346 total
Exercise/Conversion
Common Stock
2025-11-25$0.61/sh+2,796$1,720→ 183,142 total
Exercise/Conversion
Common Stock
2025-11-25$0.61/sh+94,268$57,975→ 277,410 total
Exercise/Conversion
Common Stock
2025-11-25$21.10/sh+4,739$99,993→ 282,149 total
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−2,796→ 0 total
Exercise: $0.61Exp: 2028-07-29→ Common Stock (2,796 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−94,268→ 0 total
Exercise: $0.61Exp: 2028-10-17→ Common Stock (94,268 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−43,064→ 0 total
Exercise: $6.36Exp: 2029-12-12→ Common Stock (43,064 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−4,284→ 0 total
Exercise: $21.09Exp: 2029-12-12→ Common Stock (4,284 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−3,527→ 0 total
Exercise: $28.35Exp: 2030-12-07→ Common Stock (3,527 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2025-11-25−4,739→ 0 total
Exercise: $21.10Exp: 2031-12-07→ Common Stock (4,739 underlying)

Footnotes (1)

Documents

1 file